Dextran 40

Brand names: LMD
Drug class: Antineoplastic Agents

Usage of Dextran 40

Shock

Early fluid replacement and plasma volume expansion in the adjunctive treatment of certain types of shock or impending shock (e.g., burns, surgery, hemorrhage, or other trauma in which a circulating volume deficit is present) when whole blood or blood products are not available, or when the need for haste precludes the necessary cross-matching of blood.

Minimizes sludging of blood as a result of microcirculation effects.

Not a replacement for other forms of therapy; complementary to fluids and electrolytes.

Extracorporeal Circulation

Priming fluid (alone or as an additive to other priming fluids) in pump oxygenators for perfusion during extracorporeal circulation.

Prophylaxis of Thromboembolic Disorders

Prophylaxis of venous thrombosis and pulmonary embolism for surgical procedures associated with a high risk of thromboembolic complications (e.g., hip surgery).

May be beneficial in patients undergoing hip surgery; however, has not been shown to be more effective than oral anticoagulants or heparin in patients undergoing general surgery.

The American College of Chest Physicians (ACCP) does not recommend as sole method of thromboprophylaxis in elective hip arthroplasty.

Relate drugs

How to use Dextran 40

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion. Preservative-free, single-use container; discard unused portion.

Administer 20 mL dextran 1 before administration of dextran 40. (See Sensitivity Reactions under Cautions.)

When infusing concentrated dextran 40, use an administration set with a filter. An administration set is provided with commercially available preparation; consult the manufacturer’s instructions for proper use.

Prophylaxis of Thromboembolic Disorders

Generally, initiate dextran 40 therapy during the surgical procedure.

Rate of Administration Shock

Infusion rate is dependent on patient-specific requirements (e.g., amount of fluid loss, resultant hemoconcentration). May infuse the first 500 mL (10 mL/kg) of solution rapidly if closely monitoring central venous pressure; however, infuse the remainder of the dose slowly. (See Circulatory and/or Volume Overload in Warnings.)

If not monitoring central venous pressure, infuse drug more slowly; closely observe patient for signs of circulatory overload.

Dosage

Pediatric Patients

Shock IV

Adjust dosage and rate of infusion based on individual patient requirements, amount of fluid loss and resultant hemoconcentration. (See Rate of Administration under Administration.)

Infants: 0.5 g/kg (5 mL/kg).

Children: 1 g/kg (10 mL/kg).

Adolescents: Maximum total dosage (first 24 hours) of 2 g/kg (20 mL/kg); thereafter, maximum dosage of 1 g/kg (10 mL/kg) daily for up to 5 days.

Extracorporeal Circulation IV

Infants: 0.5 g/kg (5 mL/kg).

Children: 1 g/kg (10 mL/kg).

Prophylaxis of Thromboembolic Disorders IV

Infants: 0.5 g/kg (5 mL/kg).

Children: 1 g/kg (10 mL/kg).

Adolescents: Select dosage according to the risk of thromboembolic complications (e.g., type of surgery, duration of immobilization). Generally, the day of surgery, 50–100 g (500–1000 mL [approximately 10 mL/kg]). Then, 50 g (500 mL) daily for an additional 2–3 days. Thereafter, may give 50 g (500 mL) every 2–3 days for up to 2 weeks, according to the risk of thromboembolic complications.

Adults

Shock IV

Adjust dosage and rate of infusion based on individual patient requirements, amount of fluid loss, and resultant hemoconcentration. (See Rate of Administration under Administration.)

Maximum total dosage (first 24 hours): 2 g/kg (20 mL/kg); thereafter, maximum dosage of 1 g/kg (10 mL/kg) daily for up to 5 days.

Extracorporeal Circulation IV

Usual dose: 1–2 g/kg (10–20 mL/kg); maximum 2 g/kg (20 mL/kg). The amount of solution used varies with the volume of the pump oxygenator.

Prophylaxis of Thromboembolic Disorders IV

Select dosage according to the risk of thromboembolic complications (e.g., type of surgery, duration of immobilization).

Generally, the day of surgery, 50–100 g (500–1000 mL [approximately 10 mL/kg]). Then, 50 g (500 mL) daily for an additional 2–3 days. Thereafter, may give 50 g (500 mL) every 2–3 days for up to 2 weeks, according to the risk of thromboembolic complications.

Prescribing Limits

Pediatric Patients

Shock IV

Adolescents (first 24 hours): Maximum of 2 g/kg (20 mL/kg). Thereafter, maximum of 1 g/kg (10 mL/kg) daily. Maximum duration: 5 days.

Adults

Shock IV

First 24 hours: Maximum of 2 g/kg (20 mL/kg). Thereafter, maximum of 1g/kg ( 10 mL/kg daily).

Maximum duration: 5 days.

Extracorporeal Circulation IV

Total dosage: Maximum 2 g/kg (20 mL/kg).

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time. (See Hepatic Effects under Cautions.)

Renal Impairment

In advanced renal disease, do not exceed maximum recommended dosages. (See Renal Effects, Sodium Content, and Renal Impairment under Cautions.)

Geriatric Patients

No specific dosage recommendations at this time except those related to renal impairment.

Warnings

Contraindications

  • Known hypersensitivity to dextran or any ingredient in the formulation.
  • Marked cardiac decompensation.
  • Renal disease with severe oliguria or anuria.
  • Marked hemostatic defects of all types (e.g., thrombocytopenia, hypofibrinogenemia), including those caused by drugs (e.g., heparin, warfarin).
  • Some clinicians consider extreme dehydration a contraindication to dextran 40 therapy. (See Renal Effects under Cautions.)

    • Warnings/Precautions

    Warnings

    Circulatory and/or Volume Overload

    Dextran 40 is a hypertonic colloidal solution; vascular overload may occur with large doses of dextran 40. Monitor central venous pressure closely when drug is administered by rapid infusion and in patients with poor hydration status needing additional fluid therapy.

    Immediately discontinue drug if precipitous rise in central venous pressure or any clinical signs of circulatory overloading occur.

    May cause fluid and/or solute overloading (especially when using large doses) resulting in dilution of serum electrolytes, overhydration, congested states, or pulmonary edema. Do not administer to patients with pulmonary edema; use with caution in cardiac decompensation and CHF. (See Sodium Content under Cautions.)

    Risk of dilutional states is inversely proportional to the solution’s electrolyte concentration. Risk of solute overloading, resulting in congestion with peripheral and pulmonary edema, is directly proportional to the solution’s electrolyte concentration.

    Renal Effects

    Increases viscosity and specific gravity of urine, especially in patients with decreased urine flow. Typically, specific gravity increases only slightly in adequately hydrated patients with normal renal function; however, tubular stasis and blocking reported even in adequately hydrated patients. Low specific gravity of urine during dextran therapy may indicate a failure of renal dextran clearance; discontinue dextran.

    Assess hydration before administration of dextran. Administer additional fluid if signs of dehydration are present. (See Contraindications under Cautions.)

    If decreased urinary output is secondary to shock, may use dextran 40 so long as urinary output improves after administration of the drug.

    Monitor urinary flow rates during administration; discontinue therapy if oliguria or anuria occurs and administer an osmotic diuretic to minimize vascular overloading.

    Renal failure reported, particularly in extremely dehydrated patients. May be precipitated by excessive doses in patients with advanced renal disease; do not exceed dosage recommendations. (See Contraindications under Cautions.)

    Tubular vacuolization (osmotic nephrosis) reported; possibly reversible. However, clinical importance not fully known.

    Abnormal renal function test results reported, generally in patients who have undergone surgery or cardiac catheterization. Specific effect of dextran 40 on renal function not yet determined.

    Hepatic Effects

    Abnormal hepatic function test results (increased AST and ALT) reported, generally in patients who have undergone surgery or cardiac catheterization. Specific effect of dextran 40 on hepatic function not yet determined.

    Metabolic Effects

    Mild to moderate acidosis (usually transient) may develop during perfusion with any priming fluid in pump oxygenators; is not altered by dextran 40 administration; may require an alkalinizing agent.

    Excessive Doses

    Avoid exceeding the recommended dose; possible dose-related increase of wound hematoma, wound seroma, wound bleeding (hematuria and melena), and pulmonary edema.

    Hematologic Effects

    May interfere with platelet function; use with caution in thrombocytopenia.

    Transient prolongation of bleeding time possible in patients receiving >1 L of 10% dextran 40 solution; slight increase in bleeding tendency may also occur.

    Dextran 40 causes marked factor VIII decrease and a greater decrease in factors V and IX than expected from the effects of hemodilution alone. Usually occurs at doses near 1.5 g/kg (15 mL/kg). Observe trauma and major surgery patients for early signs of bleeding complications. Slightly increased blood loss possible in postoperative patients.

    Additional blood loss may occur in patients with active hemorrhage because of the increase in perfusion pressure and improved blood flow.

    Determine hematocrit after administration of dextran 40; avoid depressing below 30% by volume.

    May cause increased rouleaux formation; draw blood samples for typing and cross-matching prior to dextran infusion. Reserve samples for subsequent use, if necessary. (See Specific Drugs and Laboratory Tests under Interactions.)

    Administration of large volumes of dextran solution results in lowered plasma protein concentrations.

    Sodium Content

    Each 500 mL of the commercially available 10% dextran 40 in 0.9% sodium chloride injection provides 77 mEq sodium. (See Specific Drugs and Laboratory Tests under Interactions.)

    Use products with sodium ions with caution in CHF, severe renal insufficiency, and edema with sodium retention. (See Renal Impairment, Renal Effects, and Circulatory and/or Volume Overload under Cautions.)

    Observe the usual precautions and contraindications associated with sodium in patients receiving 10% dextran 40 in 0.9% sodium chloride injection.

    Sensitivity Reactions

    Mild urticarial reactions reported.

    Dextran-induced Anaphylactoid Reactions

    Severe dextran-induced anaphylactoid reactions (e.g., generalized urticaria, tightness of the chest, wheezing, hypotension, nausea, vomiting, severe hypotension, shock, cardiac and respiratory arrest, death) reported rarely. Typically occur early in the infusion period in patients with no previous exposure to dextran 40, even with doses as small as 0.5 g (5 mL). Closely monitor patients with no previous exposure to dextran, especially during the first minutes of infusion.

    Administration of 20 mL of dextran 1 prior to dextran 40 infusion decreases the likelihood of anaphylactoid reactions; however, serious reactions may still occur.

    Discontinue dextran at first sign of allergic reaction so long as circulation can be maintained by other means. Immediate medical intervention (e.g., parenteral epinephrine, antihistamines, and other supportive therapy) may relieve symptoms. If circulatory collapse due to anaphylaxis occurs after discontinuing dextran, begin rapid volume substitutions with another agent.

    Keep resuscitative measures readily available during dextran use.

    General Precautions

    Local Injection Site Reactions

    Adverse local reactions caused by IV administration of dextran 40 include febrile response, infection at the injection site, venous thrombosis or phlebitis extending from the injection site, extravasation, and hypervolemia. If such reactions occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the solution for examination if deemed necessary.

    Diabetes Mellitus

    Use with caution in patients with diabetes mellitus (suBClinical or overt). (See Specific Drugs and Laboratory Tests under Interactions.)

    Observe the usual precautions and contraindications associated with Dextrose in patients receiving 10% dextran 40 in 5% dextrose injection.

    Cardiac Patients

    Dextran 40 is hazardous to heart failure patients because of the plasma volume expanding effect, especially when administered in sodium chloride. (See Sodium Content under Cautions.)

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not know whether dextran 40 is distributed into milk. Caution if used in nursing women.

    Pediatric Use

    Safety and efficacy not established in neonates.

    Renal Impairment

    Use with caution in patients with impaired renal clearance of dextran; circulatory overload possible. Risk of sodium retention in patients with renal insufficiency. (See Circulatory and/or Volume Overload, Renal Effects, and Sodium Content under Cautions.)

    What other drugs will affect Dextran 40

    Rouleaux Formation

    Dextran may increase the formation of rouleaux; draw blood samples for typing and cross-matching prior to dextran infusion. Reserve sample for subsequent use, if necessary.

    Turbidity

    Dextran in the blood may cause turbidity; turbidity may interfere with some assays.

    Specific Drugs and Laboratory Tests

    Drug or Test

    Interaction

    Comments

    Bilirubin assays using alcohol

    Dextran in the blood may cause turbidity and interfere with assay

    Draw blood samples before initiating dextran therapy

    Blood cross-match (proteolytic enzyme techniques)

    Possible interference with laboratory test; risk of rouleaux formation

    Draw blood samples before initiating dextran therapy; reserve portions for later determinations

    Blood glucose (sulfuric acid or acetic acid hydrolysis)

    Dextran 40 may cause falsely elevated values

    Draw blood samples before initiating dextran therapy

    Blood-typing and cross-match (indirect antiglobulin method)

    No interaction

    Blood-typing and cross-match (saline agglutination method)

    No interaction

    Corticosteroids

    Caution with IV fluid therapies containing sodium

    Corticotropin

    Caution with IV fluid therapies containing sodium

    Total protein assay using biuret

    Dextran in the blood may cause turbidity and interfere with assay

    Draw blood samples before initiating dextran therapy

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant